type	chrom	pos	ref	alt	gene	transcript	psyntax	csyntax	start	end	maf_ref	maf_alt	hgvsg	genomic oncokb	found genomic?	genomic elapsed (sec)	protein oncokb	found protein?	protein elapsed (sec)	hgvsg oncokb	found hgvsg?	hgvsg elapsed (sec)
SNV	chr4	54729437	C	A	KIT	ENST00000288135	p.A698E	c.2093C>A	54729437	54729437	C	A	4:g.54729437C>A		False	0.258		False	0.25		False	0.578
SNV	chr7	116739978	C	T	MET	ENST00000397752	p.T474I	c.1421C>T	116739978	116739978	C	T	7:g.116739978C>T		False	0.21		False	0.183		False	0.644
SNV	chr9	8499717	T	A	PTPRD	ENST00000381196	p.Y751F	c.2252A>T	8499717	8499717	T	A	9:g.8499717T>A		False	0.206		False	0.224		False	0.288
INDEL	chr13	32337239	CATATAAAAATGACTCTAGGTCAAG	C	BRCA2	ENST00000380152	p.I963_D970del	c.2887_2910del	32337240	32337263	ATATAAAAATGACTCTAGGTCAAG	-	13:g.32337240_32337263del		False	0.224		False	0.316		False	0.204
SNV	chr17	7674220	C	T	TP53	ENST00000269305	p.R248Q	c.743G>A	7674220	7674220	C	T	17:g.7674220C>T	The TP53 R248Q mutation is located in the protein's DNA binding domain. Expression of this mutation in TP53-null cell lines resulted in aggregation of unfolded mutant proteins, likely leading to destabilization of TP53 and upregulation of heat shock proteins (PMID: 21445056). Expression of this mutation in osteosarcoma cell lines led to a reduced apoptotic response, including reduced expression of pro-apoptotic proteins (PMID: 16778209). In biochemical assays, this mutation was found to bind DNA with a lower affinity than wildtype TP53 (PMID: 24814347).	True	0.293	The TP53 R248Q mutation is located in the protein's DNA binding domain. Expression of this mutation in TP53-null cell lines resulted in aggregation of unfolded mutant proteins, likely leading to destabilization of TP53 and upregulation of heat shock proteins (PMID: 21445056). Expression of this mutation in osteosarcoma cell lines led to a reduced apoptotic response, including reduced expression of pro-apoptotic proteins (PMID: 16778209). In biochemical assays, this mutation was found to bind DNA with a lower affinity than wildtype TP53 (PMID: 24814347).	True	0.188	The TP53 R248Q mutation is located in the protein's DNA binding domain. Expression of this mutation in TP53-null cell lines resulted in aggregation of unfolded mutant proteins, likely leading to destabilization of TP53 and upregulation of heat shock proteins (PMID: 21445056). Expression of this mutation in osteosarcoma cell lines led to a reduced apoptotic response, including reduced expression of pro-apoptotic proteins (PMID: 16778209). In biochemical assays, this mutation was found to bind DNA with a lower affinity than wildtype TP53 (PMID: 24814347).	True	0.199
INDEL	chr17	43091462	CTTGA	C	BRCA1	ENST00000357654	p.N1355Kfs*10	c.4065_4068del	43091463	43091466	TTGA	-	17:g.43091463_43091466del	Truncating mutations in BRCA1 can lead to varying C-terminally truncated proteins that results in aberrant protein folding, contributing to loss of BRCA1 protein function. Human breast cancer cell lines that contain a truncating mutation in BRCA1 display elevated levels of aneuploidy and impaired DNA damage response. In addition, truncating mutations have been shown to induce aberrant protein localization, which may impact the interaction of important binding partners (PMID: 20608970). Mouse models of BRCA1 truncating mutations develop cancer, including mammary carcinomas, lymphomas and ovarian carcinomas (PMID: 11358863, 12483515, 12947386).	True	0.203	Truncating mutations in BRCA1 can lead to varying C-terminally truncated proteins that results in aberrant protein folding, contributing to loss of BRCA1 protein function. Human breast cancer cell lines that contain a truncating mutation in BRCA1 display elevated levels of aneuploidy and impaired DNA damage response. In addition, truncating mutations have been shown to induce aberrant protein localization, which may impact the interaction of important binding partners (PMID: 20608970). Mouse models of BRCA1 truncating mutations develop cancer, including mammary carcinomas, lymphomas and ovarian carcinomas (PMID: 11358863, 12483515, 12947386).	True	0.409	Truncating mutations in BRCA1 can lead to varying C-terminally truncated proteins that results in aberrant protein folding, contributing to loss of BRCA1 protein function. Human breast cancer cell lines that contain a truncating mutation in BRCA1 display elevated levels of aneuploidy and impaired DNA damage response. In addition, truncating mutations have been shown to induce aberrant protein localization, which may impact the interaction of important binding partners (PMID: 20608970). Mouse models of BRCA1 truncating mutations develop cancer, including mammary carcinomas, lymphomas and ovarian carcinomas (PMID: 11358863, 12483515, 12947386).	True	0.224
SNV	chr22	29642262	G	C	NF2	ENST00000338641	p.A142P	c.424G>C	29642262	29642262	G	C	22:g.29642262G>C		False	0.228		False	0.254		False	0.206
INDEL	chr1	85270827	AT	A	BCL10	ENST00000648566	p.I46Yfs*24	c.136del	85270828	85270828	T	-	1:g.85270828del	Truncating mutations of BCL10 occur either within or C-terminal to the CARD domain of the protein. Experimental studies have shown that mutations within the CARD domain cannot induce cell death or activate NF-kB signaling. In contrast, mutations after the CARD domain, while retaining NF-kB signaling, failed to induce apoptosis (PMID: 9989495, 10319863).	True	0.222	Truncating mutations of BCL10 occur either within or C-terminal to the CARD domain of the protein. Experimental studies have shown that mutations within the CARD domain cannot induce cell death or activate NF-kB signaling. In contrast, mutations after the CARD domain, while retaining NF-kB signaling, failed to induce apoptosis (PMID: 9989495, 10319863).	True	0.217	Truncating mutations of BCL10 occur either within or C-terminal to the CARD domain of the protein. Experimental studies have shown that mutations within the CARD domain cannot induce cell death or activate NF-kB signaling. In contrast, mutations after the CARD domain, while retaining NF-kB signaling, failed to induce apoptosis (PMID: 9989495, 10319863).	True	0.319
INDEL	chr2	47803500	AC	A	MSH6	ENST00000234420	p.F1088Sfs*2	c.3261del	47803501	47803501	C	-	2:g.47803501del	The exon 5 MSH6 F1088Lfs*5 mutation occurs in MutS domain V of the protein. While this mutation has not been functionally characterized, insertion of a cytosine at position 3261 (codon 1088 in exon 5 of the MSH6 protein) results in a truncating frameshift mutation and has been associated with late onset endometrial cancer (PMID: 21674763, 15837969).	True	0.195	The exon 5 MSH6 F1088Lfs*5 mutation occurs in MutS domain V of the protein. While this mutation has not been functionally characterized, insertion of a cytosine at position 3261 (codon 1088 in exon 5 of the MSH6 protein) results in a truncating frameshift mutation and has been associated with late onset endometrial cancer (PMID: 21674763, 15837969).	True	0.198	The exon 5 MSH6 F1088Lfs*5 mutation occurs in MutS domain V of the protein. While this mutation has not been functionally characterized, insertion of a cytosine at position 3261 (codon 1088 in exon 5 of the MSH6 protein) results in a truncating frameshift mutation and has been associated with late onset endometrial cancer (PMID: 21674763, 15837969).	True	0.222
SNV	chr2	214767531	CA	TG	BARD1	ENST00000260947	p.V507M	c.1518_1519inv	214767531	214767532	CA	TG	2:g.214767531_214767532delinsTG		False	0.198		False	0.25		False	0.24
SNV	chr5	236534	C	T	SDHA	ENST00000264932	p.S456L	c.1367C>T	236534	236534	C	T	5:g.236534C>T		False	0.204		False	0.218		False	0.219
SNV	chr5	236561	G	A	SDHA	ENST00000264932	p.R465Q	c.1394G>A	236561	236561	G	A	5:g.236561G>A		False	0.269		False	0.207		False	0.399
INDEL	chr6	127148578	TGCCCAGAAAATGTCATTTTTTTATCTGTGATTTAACCTTTGTAATGTCTTTCTACATTTGTCTCCACAGTGCATCCTAACGTTAGTCAAGGCTGCCAAGGAGGCTGTGCAACATGCTCAGATTACAATGGATGTTTGTCATGTAA	T	RSPO3	ENST00000356698	splice_acceptor_variant	c.98-62_180del	127148579	127148723	GCCCAGAAAATGTCATTTTTTTATCTGTGATTTAACCTTTGTAATGTCTTTCTACATTTGTCTCCACAGTGCATCCTAACGTTAGTCAAGGCTGCCAAGGAGGCTGTGCAACATGCTCAGATTACAATGGATGTTTGTCATGTAA	-	6:g.127148579_127148723del		False	0.19		False	0.279		False	0.25
INDEL	chr7	2924306	GGGA	G	CARD11	ENST00000396946	p.S622del	c.1864_1866del	2924307	2924309	GGA	-	7:g.2924307_2924309del		False	0.212		False	0.2		False	0.401
INDEL	chr8	127738358	CCAG	C	MYC	ENST00000621592	p.Q52del	c.154_156del	127738359	127738361	CAG	-	8:g.127738359_127738361del		False	0.297		False	0.178		False	0.339
INDEL	chr9	136496492	TGTG	T	NOTCH1	ENST00000651671	p.P2415del	c.7244_7246del	136496493	136496495	GTG	-	9:g.136496493_136496495del	The NOTCH1 P2415del mutation occurs within the C-terminal proline, glutamic acid, serine, threonine-rich (PEST) domain, which is necessary for regulating the stability of cleaved-intracellular NOTCH1 by recruiting proteins that target it for ubiquitination and degradation (PMID: 24651013). PEST domain loss of function can thereby lead to aberrant, oncogenic accumulation of cleaved intracellular NOTCH1 (PMID: 21948802). Breast cancer PDX models and T-ALL cell lines with naturally occurring disruptions to the PEST domain have increased intracellular NOTCH1 half-life and increased NOTCH1-dependent gene expression (PMID: 15472075, 25564152) suggesting that other mechanisms of disrupting the PEST domain, such as the P2415del mutation, may have similar consequences.	True	0.219	The NOTCH1 P2415del mutation occurs within the C-terminal proline, glutamic acid, serine, threonine-rich (PEST) domain, which is necessary for regulating the stability of cleaved-intracellular NOTCH1 by recruiting proteins that target it for ubiquitination and degradation (PMID: 24651013). PEST domain loss of function can thereby lead to aberrant, oncogenic accumulation of cleaved intracellular NOTCH1 (PMID: 21948802). Breast cancer PDX models and T-ALL cell lines with naturally occurring disruptions to the PEST domain have increased intracellular NOTCH1 half-life and increased NOTCH1-dependent gene expression (PMID: 15472075, 25564152) suggesting that other mechanisms of disrupting the PEST domain, such as the P2415del mutation, may have similar consequences.	True	0.22	The NOTCH1 P2415del mutation occurs within the C-terminal proline, glutamic acid, serine, threonine-rich (PEST) domain, which is necessary for regulating the stability of cleaved-intracellular NOTCH1 by recruiting proteins that target it for ubiquitination and degradation (PMID: 24651013). PEST domain loss of function can thereby lead to aberrant, oncogenic accumulation of cleaved intracellular NOTCH1 (PMID: 21948802). Breast cancer PDX models and T-ALL cell lines with naturally occurring disruptions to the PEST domain have increased intracellular NOTCH1 half-life and increased NOTCH1-dependent gene expression (PMID: 15472075, 25564152) suggesting that other mechanisms of disrupting the PEST domain, such as the P2415del mutation, may have similar consequences.	True	0.869
INDEL	chr12	49032040	AGCT	A	KMT2D	ENST00000301067	p.Q4221del	c.12662_12664del	49032041	49032043	GCT	-	12:g.49032041_49032043del		False	0.401		False	0.316		False	0.862
INDEL	chr12	49033881	TTGC	T	KMT2D	ENST00000301067	p.Q3612del	c.10821_10823del	49033882	49033884	TGC	-	12:g.49033882_49033884del		False	1.335		False	0.233		False	0.917
INDEL	chr12	49037507	ATGC	A	KMT2D	ENST00000301067	p.Q3282del	c.9846_9848del	49037508	49037510	TGC	-	12:g.49037508_49037510del		False	1.292		False	0.201		False	0.52
INDEL	chr12	132643512	CCA	C	POLE	ENST00000320574	p.V1446Gfs*3	c.4337_4338del	132643513	132643514	CA	-	12:g.132643513_132643514del		False	1.02		False	0.442		False	0.42
INDEL	chr16	2170712	CGAG	C	TRAF7	ENST00000326181	p.E115del	c.343_345del	2170713	2170715	GAG	-	16:g.2170713_2170715del		False	0.547		False	0.216		False	0.377
INDEL	chr16	3728301	CGCT	C	CREBBP	ENST00000262367	p.Q2248del	c.6743_6745del	3728302	3728304	GCT	-	16:g.3728302_3728304del		False	0.223		False	0.251		False	0.338
INDEL	chr16	3728399	TTGC	T	CREBBP	ENST00000262367	p.Q2216del	c.6645_6647del	3728400	3728402	TGC	-	16:g.3728400_3728402del		False	0.384		False	0.291		False	0.167
INDEL	chr17	42218217	TG	T	STAT5B	ENST00000293328	p.Q368Rfs*2	c.1102del	42218218	42218218	G	-	17:g.42218218del		False	0.182		False	0.2		False	0.178
SNV	chr17	61716050	C	T	BRIP1	ENST00000259008	p.R798Q	c.2393G>A	61716050	61716050	C	T	17:g.61716050C>T		False	0.219		False	0.215		False	0.218
INDEL	chrX	49030440	TC	T	TFE3	ENST00000315869	p.G482Dfs*44	c.1445del	49030441	49030441	C	-	X:g.49030441del		False	0.214		False	0.234		False	0.163
INDEL	chrX	67545316	T	TGCA	AR	ENST00000374690	p.Q80dup	c.237_239dup	67545316	67545317	-	GCA	X:g.67545316_67545317insGCA		False	0.194		False	0.166		False	0.18
INDEL	chrX	67545316	T	TGCAGCA	AR	ENST00000374690	p.Q79_Q80dup	c.234_239dup	67545316	67545317	-	GCAGCA	X:g.67545316_67545317insGCAGCA		False	0.178		False	0.301		False	0.191
INDEL	chrX	67545316	TGCA	T	AR	ENST00000374690	p.Q80del	c.237_239del	67545317	67545319	GCA	-	X:g.67545317_67545319del		False	0.21		False	0.192		False	0.149
INDEL	chrX	67546514	TGGCGGCGGCGGCGGCGGCGGCGGCGGC	T	AR	ENST00000374690	p.G465_G473del	c.1394_1420del	67546515	67546541	GGCGGCGGCGGCGGCGGCGGCGGCGGC	-	X:g.67546515_67546541del		False	0.244		False	0.201		False	0.39
INDEL	chrX	67546514	TGGCGGCGGCGGCGGCGGCGGCGGCGGCGGC	T	AR	ENST00000374690	p.G464_G473del	c.1391_1420del	67546515	67546544	GGCGGCGGCGGCGGCGGCGGCGGCGGCGGC	-	X:g.67546515_67546544del		False	0.23		False	0.437		False	0.158
INDEL	chrX	67546514	TGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGC	T	AR	ENST00000374690	p.G463_G473del	c.1388_1420del	67546515	67546547	GGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGC	-	X:g.67546515_67546547del		False	0.274		False	0.234		False	0.166
INDEL	chrX	67546514	TGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGC	T	AR	ENST00000374690	p.G462_G473del	c.1385_1420del	67546515	67546550	GGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGC	-	X:g.67546515_67546550del		False	0.321		False	0.19		False	0.166
